In-Vitro Study Shows ReGen's Colostrinin(TM) to Have Anti-Aging & Anti-Cancer Potential.
Some of the highlights of the report are as follows:
A study undertaken by Dr. Istvan Boldogh at the University of Texas Medical Branch has indicated that Colostrinin(TM), ReGen's compound, may have an impact on the aging process and the development of cancer in addition to its known therapeutic qualities in respect to Alzheimer's disease.
The full results of an in-vitro study showing that Colostrinin(TM) reduces the spontaneous or induced mutation frequency in the DNA of cells has been published in the Journal of Experimental Therapeutics and Oncology. As such DNA damage is implicated in the general process of aging and ultimately the development of cancer, this study suggests that Colostrinin(TM) may have potential in the prevention of both processes.
Commenting on the findings, Dr. Boldogh, Department of Microbiology and Immunology at UTMB, Galveston, Texas, USA, the study's principal investigator, said, "Taken together, these results suggest that the antimutagenic properties of Colostrinin(TM) are achieved via multiple mechanisms - by decreasing intracellular levels of ROS and so preventing DNA damage and by increasing the efficiency of natural DNA repair mechanisms. These results are highly significant because natural compounds that can prevent or reduce the damage caused by such genotoxic agents when either produced by the body itself or mediated via environmental exposures are of great interest from the perspective of public health."
Commenting on the study, Percy Lomax, Chairman and Chief Executive Officer, said, "These new findings are particularly exciting and are part of the ongoing development of ReGen's compound, Colostrinin(TM). Firstly, they give yet further rationale to the marketing of Colostrinin(TM) as a nutritional supplement in the aging population, as intended through our recent deal with Metagenics. Secondly, it gives further scientific backing to the development of compounds, based on the active ingredients within Colostrinin(TM), as pharmaceutical compounds for use in specific disease conditions and suggests we may extend the disease indications we are currently exploring."
About ReGen Therapeutics Plc
ReGen Therapeutics is a UK listed Biotech company which is developing three business lines - human and veterinary nutraceuticals, prescription pharmaceuticals for the treatment of neurodegenerative diseases and a clinical research organization which oversees Phase I and Phase II both for ReGen and external customers. ReGen's business strategy is to develop its nutraceutical and pharmaceutical products to a state where they can be licensed out and marketed by a third party. Its only direct sales are currently through its clinical research organization. (www.regentherapeutics.com)
|Printer friendly Cite/link Email Feedback|
|Comment:||In-Vitro Study Shows ReGen's Colostrinin(TM) to Have Anti-Aging & Anti-Cancer Potential.|
|Date:||Sep 1, 2006|
|Previous Article:||Announcement by Vision Energy Group: Negotiations Completed on Low BTU Gas Property in Central Valley, CA.|
|Next Article:||NDS Announces New DRM Capabilities, Securely Extending pay-TV Operators' Reach Into a Range of New Platforms & Devices.|